Abstracts tagged "spondyloarthritis"

Abstract Number: 0579 • ACR Convergence 2024
Association of the Presence of Active Acute Anterior Uveitis with Disease Activity in Axial Spondyloarthritis
Judith Rademacher¹, Murat Torgutalp², Lynn zur Bonsen¹, Dominika Pohlmann¹, Hildrun Haibel¹, Fabian Proft¹, Mikhail Protopopov³, Uwe Pleyer¹, Valeria Rios Rodriguez¹ and Denis Poddubnyy⁴, ¹Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ²Charite Universitatsmedizin - Berlin, Berlin, Germany, ³Charite – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ⁴Charite-Universitatsmedizin Berlin, Berlin, Germany
Background/Purpose: Acute anterior uveitis (AAU) and axial spondyloarthritis (axSpA) are closely linked, with AAU being the most common extra-musculoskeletal manifestation of axSpA. Up to half…
Abstract Number: 1030 • ACR Convergence 2024
Diversity in Axial Spondyloarthritis Drug Trials: Examining Enrollment by Sex, Race, Ethnicity and Geographic Region
Mathieu Choufani¹, Wissam Ghusn² and Joerg Ermann³, ¹Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, MA, ²Department of Internal Medicine, Boston Medical Center, Boston, MA, ³Division of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: While axial spondyloarthritis (AxSpA) was historically perceived as a "white man's disease", it is now appreciated as a condition that can affect individuals of…
Abstract Number: 1448 • ACR Convergence 2024
The Proportion of Inflammatory Back Pain Patients with an Abnormal Sacral MRI in a Community-Based Primary Care Setting
Emmanuel Katsaros¹, Robb Russel², Melissa Nagare², Cesar Ochoa¹, Fanglong Dong¹ and Michael Weisman³, ¹Western University of Health Sciences, Pomona, CA, ²Southern California University of Health Sciences, Whittier, CA, ³Stanford University, Los Angeles, CA
Background/Purpose: Axial spondyloarthritis (axSpA) is a group of disorders typically occurring before the age of 45 whose common features include disabling inflammatory arthritis of the…
Abstract Number: 1900 • ACR Convergence 2024
Dietary Exposures Associated with Incident Spondyloarthritis
Griffin Reed, Cynthia Crowson, Ryan Lennon, John Davis and Vanessa Kronzer, Mayo Clinic, Rochester, MN
Background/Purpose: Studies have shown that diet can modify the risk of developing rheumatoid arthritis [1], but the association between diet and spondyloarthritis (SpA) remains largely…
Abstract Number: 2352 • ACR Convergence 2024
Bimekizumab Treatment Was Efficacious to 2 Years Regardless of Duration of axSpA Symptoms: Results from Two Phase 3 Studies
Sofia Ramiro¹, Fabian Proft², Raj Sengupta³, Astrid van Tubergen⁴, Anna Molto⁵, Lianne S Gensler⁶, Mitsumasa Kishimoto⁷, Vanessa Taieb⁸, Diana Voiniciuc⁹, Ute Massow¹⁰ and Victoria Navarro Compán¹¹, ¹Leiden University Medical Center, Bunde, Netherlands, ²Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ³Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ⁴Department of Medicine, Division of Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, ⁵Groupe Hospitalier Cochin, AP-HP, Paris, France, ⁶Department of Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ⁷Department of Nephrology and Rheumatology, Kyorin University School of Medicine, Tokyo, Japan, ⁸UCB Pharma, Colombes, France, ⁹UCB Pharma, Slough, United Kingdom, ¹⁰UCB Pharma, Monheim am Rhein, Germany, ¹¹La Paz University Hospital, Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain
Background/Purpose: Bimekizumab (BKZ), a monoclonal IgG1 antibody that selectively inhibits IL-17F in addition to IL-17A, showed efficacy to Week (Wk) 52 in patients (pts) with…
Abstract Number: 0069 • ACR Convergence 2024
Activation of Cardiovascular Inflammation and Wnt Signaling in Spondyloarthritis: Insights from the HLA-B27 Transgenic Rat Model
Su-Ah Yoon, Chorong Kim, Hansun Song, Mie Jin Lim and Seong-Ryul Kwon, College of Medicine, Inha University, Incheon, Republic of Korea
Background/Purpose: Despite the well-documented link between cardiovascular (CV) disease and spondyloarthritis (SpA), no animal studies have empirically validated this connection or integrated SpA, vascular inflammation,…
Abstract Number: 0538 • ACR Convergence 2024
Factors Associated with Upadacitinib Persistence and Risk Minimization Measures in Patients with Rheumatic Diseases in a Real-world Setting. UPAreal Study
Alicia Garcia Dorta¹, Cristina Rodríguez-Regalado², Andrea Hernández-Martín³, Sonia Peña-Montelongo⁴, Cristina Martínez-González¹, Elena Naveda-González⁵, Enrique González-Dávila⁶, Federico Diaz-González⁷ and Vanesa Hernández-Hernández⁸, ¹Hospital Universitario de Canarias, San Cristobal de La Laguna, Spain, ²Hospital Universitario Ntra Sra de la Candelaria, Santa Cruz de Tenerife, Spain, ³Hospital Universitario de Gran Canaria Doctor Negrín, Las Palmas, Spain, ⁴Hospital Virgen de la Peña, Fuerteventura, Spain, ⁵Hospital Universitario Dr Negrín, Las Palmas de Gran Canaria, Spain, ⁶Departamento de Matemáticas, Estadística e Investigación Operativa, Universidad La Laguna, San Cristobal de La Laguna, Spain, ⁷Hospital Universitario de Canarias, La Laguna, Spain, ⁸Hospital Universitario de Canarias, San Cristobal de La Laguna, Canarias, Spain
Background/Purpose: Upadacitinib (UPA), a Janus kinase inhibitor (JAKi) with three years of market experience, has not yet been the subject of a significant number of…
Abstract Number: 0559 • ACR Convergence 2024
Predicting Disease Flares in Axial Spondyloarthritis Using Machine Learning in the METEOR-SpA Registry
Diego Benavent¹, Victor Fanjul², Sytske Anne Bergstra³, Floris van Gaalen⁴, Maxime Dougados⁵, Umut Kalyoncu⁶, Denis Poddubnyy⁷, Clementina López Medina⁸, Konstantinos Parperis⁹, David Vega-Morales¹⁰, Desiree van der Heijde¹¹ and Victoria Navarro Compán¹², ¹Rheumatology Department, Hospital Universitari de Bellvitge, Barcelona, Spain, CAMBRILS, Spain, ²Savana Research, Madrid, ³LUMC, Leiden, Netherlands, ⁴LUMC, Leiden, Zuid-Holland, Netherlands, ⁵Rheumatology Department, Cochin Hospital and Clinical Epidemiology and Biostatistics, University of Paris, INSERM (U1153), Paris, France, ⁶Hacettepe University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey, ⁷Charite-Universitatsmedizin Berlin, Berlin, Germany, ⁸Reina Sofia University Hospital, Cordoba, Spain, ⁹University of Cyprus Medical School, Nicosia, Cyprus, ¹⁰Instituto Mexicano del Seguro Social, Monterrey, México, Monterrey, Mexico, ¹¹Department of Rheumatology, Leiden University Medical Center, Meerssen, Netherlands, ¹²La Paz University Hospital, Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain
Background/Purpose: Patients with axial spondyloarthritis (axSpA) frequently experience unforeseen disease flares that impact their quality of life. Identification of patients with high risk of flares…
Abstract Number: 0585 • ACR Convergence 2024
Cycling to TNFi vs. Switching to IL-17Ai After a First TNFi Discontinuation Among Patients with PsA and axSpA: The CorEvitas PsA/SpA Registry
Alexis Ogdie¹, Nicole Middaugh², Maya Marchese², Jessica A Walsh³, Natalia Bello⁴, Jeffrey Lisse⁴, Andris Kronbergs⁵, Elsie Grace⁶, Marcus Ngantcha⁴ and Philip Mease⁷, ¹Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²CorEvitas, LLC, Waltham, MA, ³Division of Rheumatology, Salt Lake City Veterans Affairs Health and University of Utah Health, Salt Lake City, UT, ⁴Eli Lilly and Company, Indianapolis, IN, ⁵Eli Lilly, Indianapolis, IN, ⁶Eli Lilly and Company, Indianapolis, ⁷Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA
Background/Purpose: Treatment guidelines recommend tumor necrosis factor inhibitors (TNFi) and interleukin-17A inhibitors (IL-17Ai) as options for patients with PsA or axSpA with persistent disease activity…
Abstract Number: 1031 • ACR Convergence 2024
Access to Advanced Therapies in Axial Spondyloarthritis in Latin America, Data from the PANLAR-ESPALDA Registry
Rodrigo Garcia Salinas¹, Fernando Andres Sommerfleck², Diego Vila³, Daniel Palleiro⁴, Daniel Fernández-Ávila⁵, Julio César Casasola Vargas⁶, Maria Amada Barcia⁷, Dora Liliana Candia Zuniga⁸, Nicolas Martin Marin Zucaro⁹, María Lorena Brance¹⁰ and Wilson Bautista-Molano¹¹, ¹Hospital Italiano La Plata, La Plata, Argentina, ²Sanatorio Julio Mendez, Buenos Aires, Argentina, ³Hospital Virgen del Carmen, Campana, Buenos Aires, Argentina, ⁴Instituto Nacional de Reumatologia, Montevideo, Uruguay, ⁵5Hospital San Ignacio, Colombia, BOGOTA, Colombia, ⁶Hospital General de México, “Dr.Eduardo Liceaga”, MEXICO CITY, Mexico, ⁷7Hospital General Portoviejo del Instituto Ecuatoriano de Seguridad Social (IESS), Guayaquil, Ecuador, ⁸8Hospital Regional Primero de Octubre ISSTE, Fuerzas Armadas, Mexico City, Mexico, ⁹Hospital Italiano de Buenos Aires, Capital Federal, Argentina, ¹⁰School of Medicine, Rosario National University, Argentina, Rosario, Argentina, ¹¹University Hospital Fundación Santa Fe de Bogotá, Bogotá, Colombia
Background/Purpose: Access to advanced treatments in LATAM poses challenges due to various socioeconomic factors. The PANLAR-ESPALDA registry was established with the objective of gathering data…
Abstract Number: 1452 • ACR Convergence 2024
Assessing Responsiveness of Outcome Measures for Children with Axial Juvenile Spondyloarthritis (JSpA)
Timothy Brandon¹, Rui Xiao², Cassandra Muir¹, Matthew Stoll³, Daniel Lovell⁴, Edward Oberle⁵, Nancy Chauvin⁶, Michael Francavilla⁷, Walter Maksymowych⁸ and Pamela Weiss⁹, ¹Children's Hospital of Philadelphia, Philadelphia, PA, ²University of Pennsylvania, Philadelphia, PA, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁵Nationwide Children's Hospital, Columbus, OH, ⁶The Imaging Institute @ The Cleveland Clinic, Cleveland, OH, ⁷Department of Radiology, Whiddon College of Medicine, University of South Alabama, Mobile, AL, ⁸University of Alberta, Edmonton, AB, Canada, ⁹Children's Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: Trials for patients with juvenile spondyloarthritis (JSpA) and axial disease are scarce. We assessed the responsiveness of measures for use in trials of patients…
Abstract Number: 1902 • ACR Convergence 2024
Ixekizumab for the Treatment of Patients with Spondyloarthritis – Real-world Evidence from the Nationwide Danish Registry, DANBIO
Kasper Yde Jensen¹, Merete Hetland² and Bente Glintborg³, ¹Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark, ²DANBIO and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopedics, Rigshospitalet and University of Copenhagen, Copenhagen, Denmark, Glostrup, Denmark, ³DANBIO, Rigshospitalet Glostrup and University of Copenhagen, Virum, Denmark
Background/Purpose: Clinical trials have provided robust evidence of the efficacy of ixekizumab, an IL-17 inhibitor, in improving the signs and symptoms of psoriatic arthritis (PsA)…
Abstract Number: 2359 • ACR Convergence 2024
A Real-World Study on the Clinical Characteristics and Patient Reported Outcomes of Patients with Active AxSpA Prescribed CT-P13 SC in Five European Countries
Xenofon Baraliakos¹, Ye Eun Lee², Soyeon Park², Young Nam Lee², Megan Hughes³, Molly Edwards³, Emily Quiñones⁴ and Raj Sengupta⁵, ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ²Celltrion, Inc., Incheon, Republic of Korea, ³Adelphi Real World, Bollington, United Kingdom, ⁴Adelphi Real World, Macclesfield, United Kingdom, ⁵Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom
Background/Purpose: CT-P13 SC, a new formulation of infliximab administered subcutaneously, has been approved by European Medicine Agency for the treatment of radiographic axial spondylarthritis (axSpA)…
Abstract Number: 0071 • ACR Convergence 2024
Stage-Specific Roles of Interleukin-23/Interleukin-17 Axis and Type 1 Regulatory T Cells Dynamics in Axial Spondyloarthritis
Jina Yeo¹, Min-Gang Kim², Hee Sung Kwon³, Mi Ryoung Seo¹, Hyo-Jin Choi¹, YunJae Jung⁴, Eun Young Lee⁵ and Han Joo Baek⁶, ¹Division of Rheumatology, Department of Internal Medicine, Gil Medical Center, Gachon University College of Medicine, Incheon, Republic of Korea, ²Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, Republic of Korea, ³Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea, ⁴Department of Microbiology, College of Medicine, Gachon University, Incheon, Republic of Korea, ⁵3Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea, ⁶Division of Rheumatology, Department of Internal Medicine, Gil Medical Center, Gachon University College of Medicine, Inchon, South Africa
Background/Purpose: The interleukin (IL)-23/IL-17 pathway is central to axial spondyloarthritis (axSpA) pathogenesis, yet treatments targeting IL-23 show inconsistent effectiveness across spondyloarthritis subtypes. We hypothesized that…
Abstract Number: 0539 • ACR Convergence 2024
Clinical Expression of Radiographic Axial Spondyloarthritis and Its Association with HLA-B27 in European and Ibero-American Populations: Data from the REGISPONSER and RESPONDIA Registries
Maria Angeles Puche-Larrubia¹, María Lourdes Ladehesa-Pineda², Pilar Font³, Rubén Burgos Vargas⁴, Percival Sampaio-Barros⁵, José Maldonado Cocco⁶, Anabela Barcelos⁷, Jordi Gratacos Masmitja⁸, Xavier Juanola⁹, Alejandro Escudero-Contreras³, Janitzia Vázquez Mellado⁴, Iván Arias-de la Rosa¹⁰, Eduardo Collantes-Estevez¹¹ and Clementina López Medina¹², ¹Reina Sofía University Hospital, Cordoba, Spain, ²IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Andalucia, Spain, ³IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ⁴Department of Rheumatology, Hospital General de México and Faculty of Medicine, Universidad Nacional Autónoma de México, Mexico, Mexico, ⁵Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, São Paulo, SP, Brazil, ⁶Rheumatology, Buenos Aires University School of Medicine, Buenos Aires, Argentina, ⁷Rheumatology Department, Centro Hospitalar do Baixo Vouga, Aveiro, Portugal, ⁸University Hospital Parc Taulí, Sabadell, Spain, ⁹Department of Rheumatology, Hospital Universitari de Bellvitge, Barcelona, Spain, ¹⁰Rheumatology Service, Maimonides Institute of Biomedical Research of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, Cordoba, Spain, ¹¹Rheumatology Service, Maimonides Institute of Biomedical Research of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, Cordoba 14012, Spain, ¹²Reina Sofia University Hospital, Cordoba, Spain
Background/Purpose: To date, few comparative studies have explored how ethnic and geographical differences impact the clinical presentation and management of Spondyloarthritis (SpA). Moreover, no studies…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].